These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36682511)

  • 1. Targeting of TAMs with freeze-dried monosialotetrahexosylganglioside and sialic acid-octadecylamine co-modified liposomes remodels the tumor microenvironment and enhances anti-tumor activity.
    Wei L; Zhao D; Sun W; Lin L; Sui D; Li W; Gui Y; Wang J; Deng Y; Song Y
    Eur J Pharm Biopharm; 2023 Mar; 184():50-61. PubMed ID: 36682511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
    Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
    Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.
    Meng X; Wang M; Zhang K; Sui D; Chen M; Xu Z; Guo T; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2022 Oct; 23(8):285. PubMed ID: 36258152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
    Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
    Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.
    She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y
    Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages.
    Tran NP; Tran P; Yoo SY; Tangchang W; Lee S; Lee JY; Son HY; Park JS
    Biomater Adv; 2023 Nov; 154():213606. PubMed ID: 37678087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives.
    Song Y; She Z; Huang Z; Wang S; Liu X; Zhang Q; Sun J; Di D; Deng Y
    Drug Deliv Transl Res; 2022 Mar; 12(3):647-661. PubMed ID: 33928513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylserine and/or Sialic Acid Modified Liposomes Increase Uptake by Tumor-associated Macrophages and Enhance the Anti-tumor Effect.
    Xu Z; Li J; Yan N; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2024 Jun; 25(5):125. PubMed ID: 38834759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
    Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
    Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate.
    Sun J; Song Y; Lu M; Lin X; Liu Y; Zhou S; Su Y; Deng Y
    Eur J Pharm Sci; 2016 Oct; 93():177-83. PubMed ID: 27539143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacodynamics of liposomes modified with different chain length of sialic acid derivatives].
    Song YZ; Huang ZJ; Luo X; Wang MJ; Zheng JH; Shi J; Deng YH
    Yao Xue Xue Bao; 2016 Feb; 51(2):316-24. PubMed ID: 29856587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selection of animal models influences the assessment of anti-tumor efficacy: promising sialic acid-conjugate modified liposomes demonstrate remarkable therapeutic effects in diverse mouse strains.
    Wei L; Lin L; Wang J; Guan X; Li W; Gui Y; Liao S; Wang M; Li J; Deng Y; Song Y
    Drug Deliv Transl Res; 2024 Jul; 14(7):1794-1809. PubMed ID: 38165530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy.
    Zhu S; Li X; Luo Z; Ding M; Shi S; Zhang T
    Drug Deliv Transl Res; 2024 Mar; 14(3):718-729. PubMed ID: 37679600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Fate of Sialic Acid and PEG Modified Epirubicin Liposomes in Aged versus Young Cells and Tumor Mice Models.
    Sui D; Meng X; Li C; Tang X; Qin Y; Zhang N; Ding J; Liu X; Deng Y; Song Y
    Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization design of sialic acid derivatives enhances the performance of liposomes for modulating immunosuppressive tumor microenvironments.
    Sui D; Liang K; Gui Y; Du Z; Xin D; Yu G; Zhai W; Liu X; Song Y; Deng Y
    Life Sci; 2022 Dec; 310():121081. PubMed ID: 36273630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.
    Li X; Zhu S; Yin P; Zhang S; Xu J; Zhang Q; Shi S; Zhang T
    Drug Deliv; 2021 Dec; 28(1):1849-1860. PubMed ID: 34515617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity.
    Luo X; Liu M; Hu L; Qiu Q; Liu X; Li C; Lu M; Liu Y; Zhang T; Zhou S; McClements DJ; Jia X; Deng Y; Song Y
    Int J Pharm; 2018 Aug; 547(1-2):315-329. PubMed ID: 29886095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Immunotherapy of Sialic Acid and/or GM1 Modified Coenzyme Q10 Submicron Emulsion.
    Meng X; Yan N; Guo T; Chen M; Sui D; Wang M; Zhang K; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2022 Oct; 23(8):283. PubMed ID: 36253573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y
    Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.